Suven Life Sciences Limited has informed the Exchange regarding Notice of Extraordinary General Meeting to be held on Jun 05, 2025
SUVEN · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Suven Life Sciences has called an EGM on June 5, 2025 (via video conference) with three key items for shareholder approval. Item 1 is an increase in authorized share capital from ₹30 crore to ₹50 crore (creating 20 crore additional equity shares of ₹1 each) to enable further capital raises. Item 2 is the biggest one: the company plans to issue up to 6.40 crore convertible warrants at ₹134 per warrant on a preferential basis, raising up to ~₹857.64 crore. The promoter group entity (Jasti Property and Equity Holdings, acting as trustee of Jasti Family Trust) will subscribe to ~3.18 crore warrants, with the rest going to non-promoters including Quant Mutual Fund, 3P India Equity Fund, Abakkus Diversified Alpha Fund, and several HNIs/corporates. Each warrant is convertible into 1 equity share within 18 months, and warrants unexercised will lapse. Item 3 is the re-appointment of Smt. Sudharani Jasti as Whole-time Director for 5 years (Nov 2025 to Oct 2030). The floor price was fixed at ₹133.90 based on the relevant date of May 6, 2025. Funds will be used for R&D programs, clinical development of pipeline molecules, capex for a new R&D centre, and general corporate purposes.
The ₹857+ crore preferential warrant issue is potentially dilutive for existing shareholders once converted, but the strong promoter participation (about 49.6% of the warrants) signals insider confidence. The capital raise supports Suven's growth plans in drug discovery and clinical pipeline, which is a positive long-term signal. Shareholders holding shares as of May 29, 2025 cut-off date can vote remotely between June 1 and June 4, 2025.